Ireland - English - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - spironolactone - film-coated tablet - 25 milligram(s) - aldosterone antagonists; spironolactone

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - spironolactone - film-coated tablet - 25 milligram(s) - spironolactone

Australia - English - Department of Health (Therapeutic Goods Administration)

proqualix pty ltd - in administration - spironolactone, quantity: 25 mg - tablet - excipient ingredients: maize starch; povidone; calcium sulfate dihydrate; magnesium stearate; tartrazine; sunset yellow fcf; flavour - indications for: taiwan oedema and ascites associated with congestive cardiac failure, cirrhosis of the liver, the nephrotic syndrome, malignant effusions and idiopathic oedema. essential hypertension. myasthenia gravis. primary aldosteronism.

Israel - English - Ministry of Health

teva israel ltd - spironolactone - tablets - spironolactone 25 mg - spironolactone - edematous conditions: - congestive heart failure; - cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - spironolactone - film-coated tablet - spironolactone

Canada - English - Health Canada

mint pharmaceuticals inc - spironolactone - tablet - 25mg - spironolactone 25mg - mineralocorticoid (aldosterone) receptor antagonists

Canada - English - Health Canada

mint pharmaceuticals inc - spironolactone - tablet - 100mg - spironolactone 100mg - mineralocorticoid (aldosterone) receptor antagonists

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone is indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high in this condition. spi

European Union - English - EMA (European Medicines Agency)

ceva santé animale - spironolactone - diuretics - dogs - for use in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by valvular regurgitation in dogs.

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg